Germany brings down Biogen's high-flying Tecfidera
This article was originally published in Scrip
Executive Summary
Germany's health technology appraisal institute, IQWiG, has rejected Biogen Idec's smash-hit multiple sclerosis drug Tecfidera (dimethyl fumarate). The drug, which has seen huge sales in the US, has so far failed to make the same impact in Europe.